Restless Legs Syndrome Market Share

Statistics for the 2023 & 2024 Restless Legs Syndrome market share, created by Mordor Intelligence™ Industry Reports. Restless Legs Syndrome share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Restless Legs Syndrome Industry

The restless legs syndrome market is moderately fragmented in nature due to the presence of several companies operating globally and regionally. The competitive landscape includes analyzing companies Azurity Pharmaceuticals, LLC, Glenmark Pharmaceutical, UCB S.A., Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH, Relegs, Restiffic, Viatris Inc., Psychocare Health Private Limited, and Noctrix Health, Inc. among others.

Restless Legs Syndrome Market Leaders

  1. UCB S.A

  2. Sun Pharmaceutical Industries Ltd 

  3. Boehringer Ingelheim International GmbH 

  4. Relegs

  5. Azurity Pharmaceuticals, LLC

*Disclaimer: Major Players sorted in no particular order

Restless Legs Syndrome Market Concentration

Restless Legs Syndrome Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)